Ken Nelson is a Partner at MedTech Advantage Fund with two decades of experience in digital health, medical devices, and remote monitoring. He has played a key role in the commercial success of some of the industry’s most disruptive technologies. Over the past 10 years, Ken has led go-to-market efforts in wearables and cardiac remote patient monitoring, helping build the teams and cultures behind three of the top four market share leaders: BioTelemetry (#1), iRhythm (#2), and Bardy Diagnostics (#4). His track record includes multiple successful exits, including BioTelemetry’s $2.8B acquisition by Philips and Bardy Diagnostics’ $400M+ acquisition by HillRom.
Ken also serves as a strategic advisor and judge for MedTech Innovator, the industry’s nonprofit global competition and accelerator for medical device, digital health, and diagnostic companies. Through this work, he supports the organization’s mission to improve patient lives by accelerating the growth of healthcare innovators.
